195 related articles for article (PubMed ID: 9126700)
1. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
Moon YS; Chung KC; Gill MA
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
3. The pharmacology of meropenem, a new carbapenem antibiotic.
Craig WA
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S266-75. PubMed ID: 9126702
[TBL] [Abstract][Full Text] [Related]
4. Meropenem clinical pharmacokinetics.
Mouton JW; van den Anker JN
Clin Pharmacokinet; 1995 Apr; 28(4):275-86. PubMed ID: 7648757
[TBL] [Abstract][Full Text] [Related]
5. Imipenem/cilastatin: rationale for a fixed combination.
Norrby SR
Rev Infect Dis; 1985; 7 Suppl 3():S447-51. PubMed ID: 3863220
[TBL] [Abstract][Full Text] [Related]
6. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Wiseman LR; Wagstaff AJ; Brogden RN; Bryson HM
Drugs; 1995 Jul; 50(1):73-101. PubMed ID: 7588092
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of imipenem and cilastatin in volunteers.
Rogers JD; Meisinger MA; Ferber F; Calandra GB; Demetriades JL; Bland JA
Rev Infect Dis; 1985; 7 Suppl 3():S435-46. PubMed ID: 3863219
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
[TBL] [Abstract][Full Text] [Related]
10. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
12. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
[TBL] [Abstract][Full Text] [Related]
13. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
14. Changing role of carbapenems in the treatment of lower respiratory tract infections.
Lode H; Hamacher J; Eller J; Schaberg T
Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
[TBL] [Abstract][Full Text] [Related]
16. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
17. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
Hou F; Wu G; Zheng B
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of meropenem.
Drusano GL; Hutchison M
Scand J Infect Dis Suppl; 1995; 96():11-6. PubMed ID: 7652497
[TBL] [Abstract][Full Text] [Related]
19. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
Day IP; Goudie J; Nishiki K; Williams PD
Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
[TBL] [Abstract][Full Text] [Related]
20. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
